Cytokinetics, Incorporated
Stock Forecast, Prediction & Price Target
Cytokinetics, Incorporated (CYTK) stock Price Target by analysts
$120
Potential upside: 210.15%
Cytokinetics, Incorporated price prediction
What is Cytokinetics, Incorporated stock analysts` prediction?
Cytokinetics, Incorporated stock forecast: Based on 1 Wall Street analysts` predicted price targets for Cytokinetics, Incorporated in the last 3 months, the avarage price target is $120, with a high forecast of $NaN. The average price target represents a 210.15% change from the last price of $38.69.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Cytokinetics, Incorporated stock Price Target by analysts
Full breakdown of analysts given Cytokinetics, Incorporated price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Joseph Pantginis H.C. Wainwright | 33.33% 1/3 | 12 months ago | $120 210.15% upside | $55.28 | StreetInsider | Previous targets (2) |
Paul Choi Goldman Sachs | 0% 0/1 | about 1 year ago | $60 55.07% upside | $54.56 | StreetInsider | Previous targets (0) |
Yasmeen Rahimi Piper Sandler | 50% 1/2 | over 1 year ago | $107 176.55% upside | $53.21 | StreetInsider | Previous targets (1) |
Mayank Mamtani B.Riley Financial | 0% 0/1 | over 1 year ago | $92 137.78% upside | $48.7 | StreetInsider | Previous targets (0) |
Jason Butler JMP Securities | 0% 0/2 | over 1 year ago | $78 101.60% upside | $48.3 | TheFly | Previous targets (1) |
Carter Gould Barclays | 50% 1/2 | over 1 year ago | $95 145.54% upside | $59.23 | TheFly | Previous targets (1) |
Joseph Pantginis H.C. Wainwright | 33.33% 1/3 | over 1 year ago | $90 132.61% upside | $48.71 | TheFly | Previous targets (2) |
Serge Belanger Needham | 0% 0/1 | over 1 year ago | $72 86.09% upside | $59.23 | TheFly | Previous targets (0) |
Akash Tewari Jefferies | 0% 0/1 | over 1 year ago | $85 119.69% upside | $59.23 | StreetInsider | Previous targets (0) |
Justin Kim Oppenheimer | 0% 0/1 | over 1 year ago | $106 173.97% upside | $65.27 | TheFly | Previous targets (0) |
Jason Butler JMP Securities | 0% 0/2 | over 1 year ago | $106 173.97% upside | $65.27 | TheFly | Previous targets (1) |
Salim Syed Mizuho Securities | 0% 0/1 | over 1 year ago | $99 155.88% upside | $72.74 | StreetInsider | Previous targets (0) |
Unknown Needham | N/A | almost 3 years ago | $58 49.90% upside | $45.59 | Benzinga | N/A |
Unknown Truist Financial | N/A | almost 3 years ago | $60 55.07% upside | $45.22 | Benzinga | N/A |
Dane Leone Raymond James | 50% 1/2 | about 3 years ago | $63 62.83% upside | $52.17 | Pulse 2.0 | Previous targets (1) |
Yasmeen Rahimi Piper Sandler | 50% 1/2 | over 3 years ago | $72 86.09% upside | $38.84 | TheFly | Previous targets (1) |
Joseph Pantginis H.C. Wainwright | 33.33% 1/3 | over 3 years ago | $75 93.84% upside | $39.87 | Pulse 2.0 | Previous targets (2) |
Carter Gould Barclays | 50% 1/2 | almost 4 years ago | $52 34.40% upside | $39.5 | TipRanks Contributor | Previous targets (1) |
Dane Leone Raymond James | 50% 1/2 | almost 4 years ago | $54 39.57% upside | $40.73 | StreetInsider | Previous targets (1) |
Jeffrey Hung Morgan Stanley | 100% 1/1 | almost 4 years ago | $45 16.30% upside | $38.01 | StreetInsider | Previous targets (0) |
Cytokinetics, Incorporated Financial Estimates
Cytokinetics, Incorporated Revenue Estimates
Cytokinetics, Incorporated EBITDA Estimates
Cytokinetics, Incorporated Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $70.42M N/A | $94.58M 34.30% | $7.53M -92.03% | Avg: $72.93M Low: $4.77M High: $267.01M avg. 868.53% | Avg: $383.80M Low: $23.15M High: $1.21B avg. 426.25% | Avg: $903.98M Low: $54.53M High: $2.86B avg. 135.53% | Avg: $1.55B Low: $93.92M High: $4.94B avg. 72.21% |
Net Income
% change YoY
| $-242.37M N/A | $-402.55M -66.08% | $-526.24M -30.72% | Avg: $-494.03M Low: $-588.79M High: $-258.68M avg. 6.12% | Avg: $-317.72M Low: $-569.49M High: $-4.32M avg. 35.68% | Avg: $35.39M Low: $-7.84M High: $135.42M avg. 111.13% | Avg: $332.62M Low: $-73.69M High: $1.27B avg. 839.80% |
EBITDA
% change YoY
| $-185.98M N/A | $-312.86M -68.22% | $-456.68M -45.97% | Avg: $-72.93M Low: $-267.01M High: $-4.77M avg. 84.03% | Avg: $-383.80M Low: $-1.21B High: $-23.15M avg. -426.25% | Avg: $-903.98M Low: $-2.86B High: $-54.53M avg. -135.53% | Avg: $-1.55B Low: $-4.94B High: $-93.92M avg. -72.21% |
EPS
% change YoY
| -$3.15 N/A | -$4.48 -42.22% | -$5.45 -21.65% | Avg: -$4.42 Low: -$6.1 High: -$2.68 avg. 18.95% | Avg: -$2.73 Low: -$5.9 High: -$0.04 avg. 38.11% | Avg: $0.37 Low: -$0.08 High: $1.4 avg. 113.41% | Avg: $3.45 Low: -$0.76 High: $13.19 avg. 839.80% |
Operating Expenses
% change YoY
| $96.80M N/A | $177.97M 83.85% | $173.61M -2.45% | Avg: $419.09M Low: $27.44M High: $1.53B avg. 141.39% | Avg: $2.20B Low: $133.06M High: $7.00B avg. 426.25% | Avg: $5.19B Low: $313.40M High: $16.48B avg. 135.53% | Avg: $8.94B Low: $539.73M High: $28.39B avg. 72.21% |
FAQ
What is Cytokinetics, Incorporated stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 248.18% in 2025-2028.
We have gathered data from 13 analysts. Their low estimate is -588.79M, average is -494.03M and high is -258.68M.
What is Cytokinetics, Incorporated stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 375.63% in 2025-2028.
We have gathered data from 13 analysts. Their low revenue estimate is $4.77M, average is $72.93M and high is $267.01M.
What is Cytokinetics, Incorporated stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 252.57% in 2025-2028.
We have gathered data from 13 analysts. Their low earnings per share estimate is -$6.1, average is -$4.42 and high is $-2.68.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Cytokinetics, Incorporated stock. The most successful analyst is Joseph Pantginis whose win rate is 33.33%. He has correctly predicted 1/3 price targets.